- Home
- BRKL vs AVDL Comparison
BRKL vs AVDL Comparison
Compare BRKL & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRKL
- AVDL
- Stock Information
- Founded
- BRKL 1871
- AVDL 2015
- Country
- BRKL United States
- AVDL Ireland
- Employees
- BRKL N/A
- AVDL N/A
- Industry
- BRKL Savings Institutions
- AVDL Biotechnology: Pharmaceutical Preparations
- Sector
- BRKL Finance
- AVDL Health Care
- Exchange
- BRKL Nasdaq
- AVDL Nasdaq
- Market Cap
- BRKL 897.3M
- AVDL 784.6M
- IPO Year
- BRKL 1998
- AVDL 1996
- Fundamental
- Price
- BRKL $10.24
- AVDL $9.44
- Analyst Decision
- BRKL Buy
- AVDL Strong Buy
- Analyst Count
- BRKL 2
- AVDL 6
- Target Price
- BRKL $15.25
- AVDL $18.17
- AVG Volume (30 Days)
- BRKL 474.6K
- AVDL 1.1M
- Earning Date
- BRKL 07-23-2025
- AVDL 05-07-2025
- Dividend Yield
- BRKL 5.25%
- AVDL N/A
- EPS Growth
- BRKL N/A
- AVDL N/A
- EPS
- BRKL 0.82
- AVDL N/A
- Revenue
- BRKL $338,567,000.00
- AVDL $194,450,000.00
- Revenue This Year
- BRKL $53.95
- AVDL $55.96
- Revenue Next Year
- BRKL $37.82
- AVDL $29.91
- P/E Ratio
- BRKL $12.51
- AVDL N/A
- Revenue Growth
- BRKL N/A
- AVDL 252.64
- 52 Week Low
- BRKL $8.01
- AVDL $6.38
- 52 Week High
- BRKL $13.15
- AVDL $17.30
- Technical
- Relative Strength Index (RSI)
- BRKL 42.65
- AVDL 57.99
- Support Level
- BRKL $10.14
- AVDL $8.99
- Resistance Level
- BRKL $10.52
- AVDL $9.77
- Average True Range (ATR)
- BRKL 0.22
- AVDL 0.36
- MACD
- BRKL -0.06
- AVDL -0.01
- Stochastic Oscillator
- BRKL 10.78
- AVDL 66.08
About BRKL Brookline Bancorp Inc.
Brookline Bancorp Inc operates as a multi-bank holding company. It offers commercial, business, and retail banking services, including a full complement of cash management products, online banking services, and consumer and residential loans.
About AVDL Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.